Seegene Partners with BD Life Sciences to Develop Molecular Diagnostic Assays

South Korea-based Seegene has reached an agreement with U.S. company BD Life Sciences to develop multiplex real-time PCR reagents for the BD MAX System.

Under the agreement, Seegene will develop and manufacture multiplex tests based on DPO, TOCE and MuDT technologies designed for BD’s molecular diagnostics platform, while BD will have global commercialization rights to these tests.

The BD MAX System combines and automates real-time PCR extraction, amplification and detection into a single platform capable of running a wide range of assays across multiple disease states.

Seegene says the system results in improved clinical outcomes. — Michael Cipriano